About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.
Connect with PhRMA
For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.AmericasMedicines.com
www.Facebook.com/PhRMA
www.X.com/PhRMA
The Economist
On October 4, Dr. Anne Pritchett participated in a conversation with The Economist Impact during The Art of Possible: Reimagining the Biopharmaceutical Supply Chain. The group discussed the future of the biopharmaceutical supply chain and regulatory landscape, specifically the technology and policy changes needed to prepare the biopharmaceutical industry to succeed. Reflecting on lessons learned, the group strategized on how the industry can bring medicine to patients more efficiently, even amid future crises.
When:
October 4, 2022, at 10 a.m. ET
Speakers:
- Mike Douma, Vice-President, Supply Chain and Procurement, AbbVie
- Tacy Foster, Partner, McKinsey
- Meeta Gulyani, Head of Strategy, Business Development and Sustainability, Life Science, Merck
- Alan Lovell, Senior Manager, Health, Policy, and Insights, Economist Impact
- Anne McDonald Pritchett, Senior Vice-President, Policy and Research, PhRMA
Event
Access to Medicines
The Art of the Possible: Reimagining the Biopharmaceutical Supply Chain
The Art of the Possible: Reimagining the Biopharmaceutical Supply Chain image